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ABSTRACT
Aim of the study. The pandemic state of COVID-19 has resulted in new neurological post-infection syndromes. Recently, several 
papers have reported ataxia-myoclonus syndrome following SARS-CoV-2 infection. The aim of this study was to present our two 
cases and compare them to previously reported cases. 
Materials and methods. We present two video-accompanied new cases with ataxia-myoclonus syndrome following SARS-
-CoV-2 infection and discuss the studies  published so far.  
Results. Ataxia-myoclonus syndrome, isolated myoclonus, opsoclonus-myoclonus syndrome as post-COVID-19 syndrome 
following infection have been described in 16 patients (including our two cases). Patients have been treated with intravenous 
immunoglobulins and/or steroids except for 4 patients, which resulted in a significant improvement within 1–8 weeks.
Conclusions and clinical implications. The increasing number of patients with a similar symptomatology shows a significant 
relationship between COVID-19 infection and ataxia-myoclonus syndrome. The subacute onset of neurological symptoms after 
a resolved COVID-19 infection and prominent response to immunotherapy may suggest that the neurological manifestations 
are immune-mediated. Although recovery is highly possible, it may take several weeks/months, and clinicians should be aware 
of this diagnosis and the beneficial effects of immunological treatment administered as soon as possible.
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The pandemic state of COVID -19, now having lasted 
more than 12 months, has resulted in new clinical mani-
festations and neurological post-infection syndromes of 
SARS-CoV-2 infection, involving both central and peripheral 
nervous systems [1]. The most commonly occurring in the 
acute phase of infection include ischaemic and haemorrhag-
ic strokes, cerebral venous thrombosis, posterior reversible 
encephalopathy (PRES), and those of autoimmunological 
origin presenting as Guillain-Barre, Miller Fisher syndromes 
and Bickerstaff ’s encephalitis, acute demyelinating encepha-
lomyelitis (ADEM), acute necrotising encephalopathy (ANE), 
generalised myoclonus, acute transverse myelitis, limbic 
encephalitis, and miscellaneous encephalitis [1, 2]. Recently, 
several papers have reported ataxia-myoclonus syndrome 
following SARS-CoV-2 infection (Tab. 1) [6–12]. We present 
two video-accompanied new cases of this presumably auto-
immunological syndrome. 
Case 1
A 49-year-old male, without co-morbidities besides lum-
bar surgery eight years previously, was admitted to hospital 
with involuntary movements of limbs and trunk accompanied 
by severe instability (he was almost unable to stand or walk 
independently). Eleven days before admission, the patient 
had experienced an episode of one-day fever (38º C) with 
excessive sweating without any other infection symptoms. 
These symptoms resolved spontaneously after a few days and 
he was not tested for COVID-19 infection. One week later, 
he developed hand tremors, jerky movements of all limbs, 
311www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Filip Przytuła et al., Two COVID-19-related video-accompanied cases of severe ataxia-myoclonus syndrome








   symptoms
Time between acute 
infection and  
appearance  
of  neurological 
symptoms
Treatment/outcome





11 days Methyloprednisolone 1 g/day, 5 g total followed by 
oral prednisone 60mg/day for two weeks;
significant improvement after three weeks
62/M Mild • Myoclonus
• Opsoclonus
• Ataxia
11 days IVIG 0.4 g/kg for five days,
methyloprednisolone 1g/day, 5g total followed by 
oral prednisone (1 mg/kg/day) for two weeks with 
gradual dose reduction; significant improvement  
after two weeks
Emamik-
hah et al. 
2021 [6]




2 weeks Clonazepam 0.5 mg 4x1, levetiracetam 500 mg 2 x 1, 
IVIG 2 g/kg, total dose 150 g; 
complete recovery after four weeks
54/M Moderate • Myoclonus
• Ataxia
4 days Levetiracetam 2,000 mg/day, sodium valproate  
1,000 mg/day
IVIG in total dose 100 g; Partial recovery after  
one week
52/M Moderate • Myoclonus 
• Ataxia
• Voice tremor
16 days Sodium valproate 1,000 mg/day.
clonazepam 1mg 4 x 1; 
partial recovery after two months
42/F Mild • Myoclonus
• Ataxia
• Voice tremor
10 days Sodium valproate,
clonazepam; 
no data




3 days Sodium valproate, clonazepam, IVIG; complete  
recovery after two months
52/M Mild • Myoclonus
• Ataxia
• Voice tremor
3 weeks Clonazepam, IVIG in total dose of 100 g; significant 
improvement after four weeks




10 days Levetiracetam, sodium valproate, clonazepam,
IVIG, dexamethasone; no data
Wright 
et al. 2020 
[7]
79/M Mild • Opsoclonus
• Ataxia
• Cognitive impairment
13 days No data; improvement of  cognitive function and re-
solution of eye movement abnormality after 19 days; 
death after 27 days due to general physical decline
Dijkstra 
et al. 2020 
[8]
44/M Mild • Myoclonus
• Ataxia
• Voice tremor
• Transient ocular flutter 
(no evident opsoclonus)
• Cognitive impairment
1 week Methyloprednisolone 1 g daily for five days,  
IVIG 0.4 g/kg for three days; partial recovery after  
15 days, full recovery within two months
Schel-
lekens  
et al. 2020 
[9]
48/M Mild • Myoclonus
• Ataxia
• Saccadic intrusions of eye 
movement (no opsoclo-
nus)
13 days Levetiracetam; partial recovery within two months
Foucard 
et al. [10]




10 days IVIG 0.4 g/kg for five days, steroids 1g/day for five 
days, diazepam; significant improvement after one 
week
63/M No data • Myoclonus
• Ataxia
• Ataxic dysarthria
6 weeks IVIG 0.4 g/kg for five days; significant improvement
after one week
Shah 








3 weeks Methylprednisolone 1 g/day, sodium valproate  
20 mg/kg/day, clonazepam 2 mg/day, levetiracetam  
2 g/day; recovery within one week
Grimaldi 
et al. 2020 
[5]
72/M Moderate • Myoclonus
• Ataxia
• Ataxic dysarthria
17 days IVIG 0.4 g/kg/day for five days, methyloprednisolone  
1 g/day for five days; recovery within two weeks
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and posture and gait instability with diarrhoea lasting for 
three days. Because of these symptoms, he was admitted to 
the Emergency Unit (EU). On neurological examination, he 
presented dysarthria with voice tremor, generalised myoclonus 
exacerbated by intentional movements, bilateral limb ataxia 
and wide-based gait (see video, segment 1). In the EU he was 
treated with clonazepam 1mg i.v., biperiden 2 mg p.o. and 
levetiracetam 500 mg i.v. but with no effect. Nasopharyngeal 
RT-PCR test for SARS-CoV-2 was negative. Brain computer 
tomography (CT) and magnetic resonance imaging (MRI), 
as well as a general examination of cerebrospinal fluid (CSF), 
were normal. Antibodies testing (blood and CSF) for NMDAR, 
VGKC, Borrelia burgdorferi IgG and IgM antibodies were 
negative. Viral neurological panel (Adenovirus, CMV, EBV, 
HSV-1, HSV-2, VZV, Enterovirus, Parechovirus, Parvovirus 
B19, HHV-6, HHV-7) and soluble antigens in CSF were also 
negative. Oligoclonal bands in CSF showed type 4 according to 
the Charcot Foundation. Blood laboratory tests for onconeural 
antibodies (anti-Hu, anti-Ri, Anti-Yo), anti-nuclear antibodies 
(ANA) were negative, and vitamin B12, B1 and folic acid were 
within normal ranges. 
Due to the infection episode 11 days before admission, 
serum level of SARS-CoV-2 IgG and IgM antibodies testing 
was performed, with a positive result for IgG (IgG 38.6AU/ml, 
IgM 2.2 AU/ml). Treatment with intravenous methylopredni-
solone (1g/day for five consecutive days, 5 g in total) followed 
by oral prednisone (60 mg/day) for two weeks and motor 
rehabilitation resulted in a significant improvement after three 
weeks (see video, segment 2).  
Case 2
A 62-year-old male with a history of arterial hyperten-
sion, benign prostatic hyperplasia, and kidney stones, was, 
11 days after resolution of a COVID-19 infection confirmed 
with a nasopharyngeal RT-PCR test, admitted to the EU with 
imbalance, gait disturbance, generalised tremor and ataxia. On 
neurological examination, he had jerky oscillatory movements 
of eyes (diagnosed as opsoclonus), generalised myoclonus 
and ataxia. This made the patient unable to stand or walk 
independently (see video, segment 3). Head MRI with MRI-
angiography as well as general CSF examination were normal. 
Fast CSF tests for the presence of viral (CMV, Enterovirus, 
HSV-1, HSV-2, HHV-6, Parechovirus, VZV) and bacterial 
(E. coli, H. influenzae, L. monocytogenes, N. meningitidis, 
S. agalactiae, S. pneumoniae) antigens were negative as well. 
Auto-immune encephalitis antibodies in serum (NMDAR, 
AMPAR 1 and 2, CASPR 2, LGI-1, GABA-B receptor), Borrelia 
IgM and IgG antibodies and onconeural antibodies (anti-Hu, 
anti-Ri, Anti-Yo, anti-PNMA2, anti-CV2, anti-amphiphysin) 
were not detected. Ganglioside antibody panel was nega-
tive. Chest and abdomen CT were normal. Tumour markers 
(CA-125, CA-19-9, CEA) were negative. Electroencephalog-
raphy (EEG) on admission showed bilateral theta waves in the 
central and frontal areas which resolved at release. Treatment 
with intravenous methyloprednisolone (1g/day, 5g in total) was 
initiated followed by intravenous immunoglobulins (IVIG) 
for five days (0.4 g/kg) and oral prednisone (1 mg/kg/day) 
for two weeks with gradual dose reduction. The administered 
treatment and motor rehabilitation resulted in a significant 
improvement after two weeks (see video, segment 4).
Discussion 
Understanding regarding the neurological complications 
of SARS-CoV-2 infection is still limited. Brain damage can be 
caused by hypoxia, direct brain invasion of the coronavirus, 
or post-infectious autoimmune mechanisms. The hypothesis 
of a possible neuroinvasiveness of SARS-CoV-2 causing neu-
rological symptoms during the acute state of the infection has 
been proposed [2]. Widespread neuronal ACE2 expression in 
brainstem cardiorespiratory neurons, motor cortex, the raphe 
nucleus, and others may suggest the direct invasion of virus, 
which may result in diverse neurological symptoms. 
While ACE2’s role in the brain is incompletely under-
stood, this diverse central nervous expression pattern may 
provide SARS-CoV-2, and other CoVs, with a ‘port of entry’ 
into the brain [3]. On the other hand, opsoclonus-myoclonus 
syndrome (OMS) is a rare disorder of apparently autoimmune 
paraneoplastic or parainfectious aetiology. This presents with 
opsoclonus, limbs and trunk myoclonus, and ataxia. Paraneo-
plastic OMS is generally observed in patients with breast ade-
nocarcinoma or small cell lung carcinoma, while parainfectious 
OMS has been observed in patients with HIV, Mycoplasma 
pneumoniae, Salmonella enterica, rotavirus, cytomegalovi-
rus, human herpesvirus 6, hepatitis C, and Rickettsia conorii. 
Treatment with corticosteroids or IVIG is usually successful [4]. 
Therefore, its aetiology is considered to be autoimmunological.
The subacute onset of neurological symptoms after re-
solved COVID-19 infections (however, only 11 days after) in 
both presented cases, and the prominent response to immuno-
therapy, may suggest that the neurological manifestations are 
immune-mediated. However, it is difficult to entirely exclude 
a direct viral effect of COVID-19, given that we know that 
acute COVID infection can benefit from steroids. The brain 
18F-FDG-PET (fluorodeoxyglucose Positron Emission Tomo-
graphy) study of a patient with ataxia-myoclonus syndrome as-
sociated with COVID-19 performed by Grimaldi et al. showed 
a diffuse pattern compatible with encephalitis and especially 
cerebellitis. Moreover, nerve tissue immunostaining with se-
rum and CSF showed the presence of autoantibodies directed 
against the nuclei of Purkinje cells, striatal and hippocampal 
neurons. The titre of the IgG autoantibodies in serum and 
CSF was high (serum 1/25,000, CSF 1/96) and both in serum 
and CSF the same intensity and reactivity were observed 
at the same IgG concentration [5]. These observations may 
confirm the autoimmune origin of the post-COVID-19 ataxia- 
-myoclonic syndrome. 
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Ataxia-myoclonus syndrome, isolated myoclonus, OMS 
as post-COVID-19 syndrome following infection have been 
described in several case series and reports (Tab. 1). The in-
creasing number of patients with a similar symptomatology 
suggests that there may be a significant relationship between 
infection and the described neurological symptoms, adding 
SARS-CoV-2 to the list of possible pathogens. Because re-
covery is highly possible, although it may take several weeks/ 
/months, clinicians should be aware of this diagnosis and the 
beneficial effects of immunological treatment administered 
as soon as possible.
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